Jump to content

Draft:HemoHIM

From Wikipedia, the free encyclopedia

HemoHIM

HemoHIM is a herbal dietary supplement developed in South Korea. It is marketed by Atomy Corporation.

History and Development

HemoHIM was developed by Kolmar BNH, a joint venture between Kolmar Korea and the Korea Atomic Energy Research Institute (KAERI), with funding from the South Korean government. Research began in 1997 at KAERI's Food Science Biotechnology Team. The initial goal was to strengthen the immune systems of researchers exposed to radiation in their work on nuclear energy.

After eight years of research, the HemoHIM compound was formulated in 2002. It is composed of extracts from three traditional Korean plants:

- Angelica gigas Nakai (Korean giant angelica)

- Cnidium officinale Makino (Cnidium officinale)

- Paeonia japonica Miyabe (Japanese peony)

The development process consisted of optimizing the extraction and combination of active compounds from these plants to create a standardized compound. In 2006, HemoHIM received approval from the Korean Ministry of Food and Drug Safety (MFDS).

Studies and Claims

Several studies have been conducted on HemoHIM, some of which have been published in scientific journals.

These studies explore the potential effects of HemoHIM on a variety of aspects, including:

- Natural Killer (NK) cell activity: Studies suggest that HemoHIM may stimulate the activity of these cells, which play an important role in the immune system.

- Cytokine production: Research has examined the influence of HemoHIM on the production of certain cytokines, signaling molecules involved in communication between immune cells.

- Fatigue reduction: Studies have been conducted in specific populations, such as cancer patients undergoing chemotherapy or elderly women, suggesting a possible reduction in fatigue.

It is important to note that the majority of these studies were conducted in vitro (in the laboratory) or in animal models. Larger and more rigorous clinical studies in human populations are needed to fully confirm these results and establish the clinical efficacy of HemoHIM.

Regulatory status and safety

HemoHIM is classified as a dietary supplement in many countries. In South Korea, it was the first dietary supplement to receive individual approval for its effect on improving immune function. It has also obtained certifications from other regulatory agencies, including the FDA in the United States.

Like any dietary supplement, HemoHIM may potentially interact with medications or be contraindicated in certain situations. It is therefore recommended to consult a health professional before starting its consumption, particularly in case of pre-existing health conditions or taking medications. Vigilance is also required regarding counterfeits.

References and sources

- Kim, B. K., et al. (2004). Immunomodulatory activity of a herbal preparation (HemoHIM) on natural killer cell activity in cancer patients. Immunopharmacology and immunotoxicology, 26(4), 519-535.

- Park, H. Y., et al. (2009).Radioprotective effect of HemoHIM in mice. Journal of medicinal foods, 12(2), 260-265.

- Song, G. Y., et al. (2003). HemoHIM enhances the production of Th1 cytokines and IFN-γ in mouse splenocytes. Journal of ethnopharmacology, 88(2-3), 263-269.

-Jo, S.K., et al. (2010).Effect of HemoHIM on fatigue in cancer patients undergoing chemotherapy. Korean journal of oriental physiology & pathology, 24(5), 819-824.

- Kim, H.J., et al. (2012).The effect of HemoHIM on fatigue and sleep quality in elderly women. Journal of Korean Academy of Nursing, 42(4), 541-550.

- Choi, E. M., et al. (2017). HemoHIM, a herbal preparation, alleviates airway inflammation caused by cigarette smoke and lipopolysaccharide. BMC complementary and alternative medicine, 17(1), 1-9.

https://mt.atomy.com/content/18?lang=en

https://thesun.my/spotlight/atomy-hemohim-developed-for-better-health-AM9529299

https://pubmed.ncbi.nlm.nih.gov/?term=HemoHim&sort

https://scholar.google.fr/scholar?hl=fr&as_sdt=0%2C5&q=HemoHIM&btnG=